Medical Affairs, Johnson & Johnson Private Limited, Mumbai, Maharashtra, 400080, India.
Published: February 2024
AI Article Synopsis
Article Abstract
To assess the safety and effectiveness of daratumumab monotherapy in Indian patients with relapsed/refractory multiple myeloma. In this prospective, multicenter, phase IV study, patients (aged ≥18 years) received intravenous daratumumab (16 mg/kg) in six cycles. Safety was the primary end point. Of the 139 patients included, 121 (87.1%) experienced ≥1 treatment-emergent adverse events (TEAEs; 53 [38.1%] drug-related), 32 (23%) had ≥1 serious TEAEs (five [3.6%] drug-related) and 16 (11.5%) deaths were reported (one death [0.7%] was drug-related). Overall response rate was 26.3%; 62.7% of patients had stable disease. Median time to first response and median progression-free survival were 5.2 and 5.9 months, respectively. Functional status and well-being were improved. Daratumumab showed an acceptable and expected safety profile with consistent efficacy, providing a novel therapeutic option for relapsed/refractory multiple myeloma management in India.
Department of Electronics and Computer Engineering, Faculty of Electrical Engineering, Universiti Teknologi Malaysia, Johor Bahru, Johor 81310 UTM, Malaysia.
Malaria is endemic in poverty-stricken regions of the world, and most diagnosis reveal comorbidity with other infectious diseases some of which manifest as a deformity of the structural arrangement of the Red Blood Cells (RBCs) during thin blood smear microscopy. This common occurring deformity is termed rouleaux formation, and it is the stacking together of RBCs like chains of coins. The presence of rouleaux formation indicates either a bacterial infection, connective tissue disease, chronic liver disease, multiple myeloma or diabetes among others, it is a highly common occurrence in malaria infected patients and according to the international council for standardization of hematology (ICSH), microscopists are mandated to report its presence.
Introduction: Prior studies have evaluated the level of evidence behind treatment options listed in the National Comprehensive Cancer Network (NCCN) guidelines, but no study has categorized the life cycle of regimens listed in the NCCN guidelines. We longitudinally assessed the life cycle for each regimen for newly diagnosed multiple myeloma. We track the date of first clinical data, the date of regimen addition to NCCN guidelines, the date phase 3 data (if performed) were reported, and the results of phase 3 trials.
DREAMM-11 (NCT03828292) was a Phase 1, open-label, dose-escalation study of belantamab mafodotin in Japanese patients with relapsed/refractory multiple myeloma (RRMM). In Part 1, belantamab mafodotin monotherapy (2.5 or 3.
Background: Circular RNAs (circRNAs) act as vital players in multiple myeloma (MM). Herein, we focused on the function of hsa_circ_0003489 (circ_0003489) in MM development and bortezomib (BTZ) resistance.
Methods: Relative RNA levels were detected by quantitative real-time polymerase chain reaction (qRT-PCR).
Background: Hetrombopag is a novel thrombopoietin receptor agonist that has shown an additive effect in stimulating platelet production when combined with recombinant human thrombopoietin (rhTPO). But it remains unclear whether this combination can promote hematopoietic reconstruction after autologous stem cell transplant (ASCT).
Purpose: To compare the effect of recombinant human thrombopoietin (rhTPO) plus thrombopoietin receptor agonists (TPO-RA) versus rhTPO alone on hematopoietic recovery, adverse events, post-operative complications, and cost effectiveness in patients with newly diagnosed multiple myeloma (NDMM) undergoing autologous stem cell transplant (ASCT).
